
CPIX — Cumberland Pharmaceuticals Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$6.70
+$0.14 (+2.13%)
Cumberland Pharmaceuticals Inc (CPIX) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by A. J. Kazimi MBA, based in 1600 West End Avenue, Nashville, TN, United States, 37203, with about 93 employees. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Latest reported CPIX revenue for 2025-09-30 was $8.3M. Net income was -$1.9M. Revenue was down 23.5% from 2025-06-30 to 2025-09-30. CPIX currently screens at market cap $86.9M.
Use this CPIX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CPIX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CPIX SEC filings page. Lician reads the product cache first so this HTML stays unique to Cumberland Pharmaceuticals Inc even when a live quote feed is slow.
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
CPIX Key Statistics
Market Cap
$86.90M
Volume
24,113
Previous Close
$7.84
Day Range
$7.63 – $8.46
EPS
-$0.14
Revenue
$10.44M
Net Income
-$1.90M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+11.6%
Profit Margin
-18.2%
Employees
93
CPIX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $10.44M | $9.35M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$1.90M | -$6.30M |
| EPS (Diluted) | -$0.14 | -$0.44 |
Total Assets
$75.58M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$17.96M
Operating Cash Flow
-$612.19K
Free Cash Flow
$0.00
Cumberland Pharmaceuticals Inc Company Information
- Founder, Chairman, President & CEO
- A. J. Kazimi MBA
- Headquarters
- 1600 West End Avenue, Nashville, TN, United States, 37203
- Website
- www.cumberlandpharma.com
- Phone
- 615 255 0068
- IPO / Founded
- 2009-08-11
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic